The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Sarepta Therapeutics (NASDAQ:SRPT) surges 40% post-market after strategic restructuring, workforce cuts, pipeline focus, and ...

It has been about a month since the last earnings report for Sarepta Therapeutics (SRPT). Shares have added about 7.7% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

High-rolling investors have positioned themselves bullish on Sarepta Therapeutics (NASDAQ:SRPT), and it's important for retail traders to take note. \This activity came to our attention today ...

Sarepta Therapeutics (NASDAQ:SRPT) has been analyzed by 14 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a concise ...

14 analysts have expressed a variety of opinions on Sarepta Therapeutics (NASDAQ:SRPT) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides a ...

Across the recent three months, 26 analysts have shared their insights on Sarepta Therapeutics (NASDAQ:SRPT), expressing a variety of opinions spanning from bullish to bearish.The table below ...

In recent trading, shares of Sarepta Therapeutics Inc (Symbol: SRPT) have crossed above the average analyst 12-month target price of $161.00, changing hands for $163.85/share. When a stock reaches ...

Throughout the last three months, 12 analysts have evaluated Sarepta Therapeutics (NASDAQ:SRPT), offering a diverse set of opinions from bullish to bearish.The table below provides a concise ...

Sarepta Therapeutics (NASDAQ: SRPT), a midcap biotech company, was riding high 18 months ago. The company was awaiting a crucial regulatory approval from the U.S. Food and Drug Administration (FDA ...

Sarepta Therapeutics (NASDAQ: SRPT) and Vertex Pharmaceuticals (NASDAQ: VRTX) have a lot in common: Both operate in the tricky biotech industry, and both seek to develop treatments primarily for ...

A look at the shareholders of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) can tell us which group is most powerful. The group holding the most number of shares in the company, around 84% to be ...